The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia.

IF 3.3 3区 医学 Q2 MICROBIOLOGY
Cody F Price, John P Wood, Ibrahim Ismail, Simon Smith, Josh Hanson
{"title":"The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia.","authors":"Cody F Price, John P Wood, Ibrahim Ismail, Simon Smith, Josh Hanson","doi":"10.3390/pathogens13110943","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction</b>: Patients receiving biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for rheumatological conditions are at an increased risk of serious, potentially life-threatening, infection. However, the incidence, aetiology, and clinical course of serious infection in patients receiving b/tsDMARDs in tropical settings are incompletely defined. <b>Methods</b>: We retrospectively reviewed all patients with rheumatoid arthritis receiving b/tsDMARDs between October 2012 and October 2021, at Cairns Hospital in tropical Australia. The incidence, aetiology, and clinical course of serious infections (those requiring admission to hospital or parenteral antibiotics) were determined. <b>Results</b>: 310 patients had 1468 patient years of b/tsDMARD therapy during the study period; 74/310 (24%) had 147 serious infections translating to an overall risk of 10.0 episodes of serious infection per 100 patient years. The respiratory tract (50/147, 34%) and skin (37/147, 25%) were the most frequently affected sites. A pathogen was identified in 59/147 (40%) episodes and was most commonly <i>Staphylococcus aureus</i> (24/147, 16%). Only 2/147 (1%) were confirmed \"tropical infections\": 1 case of <i>Burkholderia pseudomallei</i> and 1 case of mixed <i>B. pseudomallei</i> and community-acquired <i>Acinetobacter baumannii</i> infection. Overall, 13/147 (9%) episodes of serious infection required Intensive Care Unit admission (0.9 per 100-patient years of b/tsDMARD therapy) and 4/147 (3%) died from their infection (0.3 per 100-patient years of b/tsDMARD therapy). The burden of comorbidity and co-administration of prednisone were the strongest predictors of death or a requirement for ICU admission. <b>Conclusions</b>: The risk of serious infection in patients taking b/tsDMARDs in tropical Australia is higher than in temperate settings, but this is not explained by an increased incidence of traditional tropical pathogens.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597851/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pathogens13110943","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Patients receiving biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for rheumatological conditions are at an increased risk of serious, potentially life-threatening, infection. However, the incidence, aetiology, and clinical course of serious infection in patients receiving b/tsDMARDs in tropical settings are incompletely defined. Methods: We retrospectively reviewed all patients with rheumatoid arthritis receiving b/tsDMARDs between October 2012 and October 2021, at Cairns Hospital in tropical Australia. The incidence, aetiology, and clinical course of serious infections (those requiring admission to hospital or parenteral antibiotics) were determined. Results: 310 patients had 1468 patient years of b/tsDMARD therapy during the study period; 74/310 (24%) had 147 serious infections translating to an overall risk of 10.0 episodes of serious infection per 100 patient years. The respiratory tract (50/147, 34%) and skin (37/147, 25%) were the most frequently affected sites. A pathogen was identified in 59/147 (40%) episodes and was most commonly Staphylococcus aureus (24/147, 16%). Only 2/147 (1%) were confirmed "tropical infections": 1 case of Burkholderia pseudomallei and 1 case of mixed B. pseudomallei and community-acquired Acinetobacter baumannii infection. Overall, 13/147 (9%) episodes of serious infection required Intensive Care Unit admission (0.9 per 100-patient years of b/tsDMARD therapy) and 4/147 (3%) died from their infection (0.3 per 100-patient years of b/tsDMARD therapy). The burden of comorbidity and co-administration of prednisone were the strongest predictors of death or a requirement for ICU admission. Conclusions: The risk of serious infection in patients taking b/tsDMARDs in tropical Australia is higher than in temperate settings, but this is not explained by an increased incidence of traditional tropical pathogens.

澳大利亚热带地区类风湿性关节炎患者在接受生物和靶向合成疾病修饰抗风湿药物治疗时并发严重感染的发病率、病因和临床过程。
导言:接受生物和靶向合成改变病情抗风湿药物(b/tsDMARDs)治疗风湿病的患者发生严重感染的风险增加,甚至可能危及生命。然而,在热带地区接受 b/tsDMARDs 治疗的患者严重感染的发生率、病因和临床过程尚未完全明确。方法:我们对澳大利亚热带地区凯恩斯医院 2012 年 10 月至 2021 年 10 月期间接受 b/tsDMARDs 治疗的所有类风湿关节炎患者进行了回顾性研究。确定了严重感染(需要入院治疗或使用肠外抗生素)的发生率、病因和临床过程。研究结果310名患者在研究期间接受了1468个病程的b/tsDMARD治疗;74/310(24%)名患者发生了147次严重感染,即每100个病程中发生10.0次严重感染。呼吸道(50/147,34%)和皮肤(37/147,25%)是最常受影响的部位。59/147(40%)次感染中确定了病原体,其中最常见的是金黄色葡萄球菌(24/147,16%)。只有 2/147 例(1%)被证实为 "热带感染":1例为假马来伯克霍尔德菌,1例为假马来伯克霍尔德菌和社区获得性鲍曼不动杆菌混合感染。总体而言,13/147 例(9%)严重感染病例需要入住重症监护病房(每 100 个接受 b/tsDMARD 治疗的患者中有 0.9 例),4/147 例(3%)患者死于感染(每 100 个接受 b/tsDMARD 治疗的患者中有 0.3 例)。合并症负担和联合应用泼尼松是死亡或需要入住重症监护室的最主要预测因素。结论在澳大利亚热带地区服用 b/tsDMARDs 的患者发生严重感染的风险高于温带地区,但这并不是因为传统热带病原体的发病率增加所致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathogens
Pathogens Medicine-Immunology and Allergy
CiteScore
6.40
自引率
8.10%
发文量
1285
审稿时长
17.75 days
期刊介绍: Pathogens (ISSN 2076-0817) publishes reviews, regular research papers and short notes on all aspects of pathogens and pathogen-host interactions. There is no restriction on the length of the papers. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible. Full experimental and/or methodical details must be provided for research articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信